Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,501 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A dopamine D1-like receptor-specific agonist improves the survival of septic mice.
Tanaka K, Choudhury ME, Kikuchi S, Takeda I, Umakoshi K, Miyaue N, Mikami K, Takenaga A, Yagi H, Shinabe R, Matsumoto H, Yano H, Nagai M, Takeba J, Tanaka J. Tanaka K, et al. Among authors: yagi h. iScience. 2024 Mar 27;27(4):109587. doi: 10.1016/j.isci.2024.109587. eCollection 2024 Apr 19. iScience. 2024. PMID: 38623339 Free PMC article.
Toxoplasmic encephalitis with high 201Tl uptake and retention mimicking malignant lymphoma in a patient with human immunodeficiency virus infection.
Nakamura S, Hara K, Kobayashi T, Sumitani R, Oura M, Maeda Y, Sogabe K, Yagi H, Takahashi M, Fujii S, Harada T, Bando Y, Abe M, Miki H. Nakamura S, et al. Among authors: yagi h. Parasitol Int. 2024 Apr 12;101:102895. doi: 10.1016/j.parint.2024.102895. Online ahead of print. Parasitol Int. 2024. PMID: 38614255
Identification of potential C1-binding sites in the immunoglobulin CL domains.
Yanaka S, Kodama A, Nishiguchi S, Hiramine R, Shen J, Boonsri P, Sung D, Isono Y, Yagi H, Miyanoiri Y, Uchihashi T, Kato K. Yanaka S, et al. Among authors: yagi h. Int Immunol. 2024 Apr 2:dxae017. doi: 10.1093/intimm/dxae017. Online ahead of print. Int Immunol. 2024. PMID: 38564192
Efficacy of elotuzumab for multiple myeloma deteriorates after daratumumab: a multicenter retrospective study.
Nakamura N, Arima N, Takakuwa T, Yoshioka S, Imada K, Fukushima K, Hotta M, Fuchida SI, Kanda J, Uoshima N, Shimura Y, Tanaka H, Ohta K, Kosugi S, Yagi H, Yoshihara S, Yamamura R, Adachi Y, Hanamoto H, Shibayama H, Hosen N, Ito T, Shimazaki C, Takaori-Kondo A, Kuroda J, Matsumura I, Hino M; Kansai Myeloma Forum. Nakamura N, et al. Among authors: yagi h. Ann Hematol. 2024 Mar 16. doi: 10.1007/s00277-024-05705-z. Online ahead of print. Ann Hematol. 2024. PMID: 38492020
1,501 results